Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease
Drug Development Research · 2026
DOI: 10.1002/ddr.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Madala Ramesh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, India. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Triazoles, Pyrazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to gradual deterioration of cognitive functions. Cholinesterase enzymes play a critical role in regulating acetylcholine levels in the brain, and their dysfunction leads to impaired cholinergic neurotransmission, which is a primary hallmark of AD and contributes significantly to the cognitive decline and dementia. Here, a series of pyrazine‐1,2,3‐triazole molecular hybrids incorporating a trifluoromethyl (‐CF 3 ) group were synthesized ( 8a–o ). Synthesized compounds were then evaluated in vitro for cytotoxicity and cholinesterase inhibitory activities. All synthesized compounds were found to be nontoxic toward BV‐2 cells in the cytotoxicity screening. The in vitro inhibition assays revealed that these derivatives exhibited greater inhibitory potency against acetylcholinesterase (AChE) than butyrylcholinesterase (BuChE). Among them, compound 8h demonstrated the most potent AChE inhibition compared to BuChE ( AChE, IC 50 = 5.43 µM; BuChE, IC 50 = 127.12 µM ). The most active compound 8h was further subjected to molecular docking and dynamic simulation (100 ns) to investigate its binding affinity, thermodynamic behavior, and stability within the active site of cholinesterase enzymes. Overall, the findings suggested that the synthesized compounds represent promising drug candidates as selective acetylcholinesterase inhibitors for the treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, India.
- Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology, Hyderabad, India.
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmacy, Shirpur, Maharashtra, India.
- Department of Pharmaceutical Chemistry, Rajarshi Shahu College of Pharmacy, Buldana, Maharashtra, India.
ORCID-Profile: Madala Ramesh, Pannala Padmaja, Vinod Ugale, Atul Shirkhedkar, Rahul Pawara, Deepak Lokwani, Srinivas Manda, Pedavenkatagari Narayana Reddy
Zitieren
APA
Ramesh, M., Padmaja, P., Ugale, V., Shirkhedkar, A., Pawara, R., Lokwani, D., Manda, S., & Reddy, P. N. (2026). Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70249
Vancouver
Ramesh M, Padmaja P, Ugale V, Shirkhedkar A, Pawara R, Lokwani D, et al. Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Drug Development Research. 2026. doi:10.1002/ddr.70249
BibTeX
@article{Ramesh2026,
author = {Ramesh, Madala and Padmaja, Pannala and Ugale, Vinod and Shirkhedkar, Atul and Pawara, Rahul and Lokwani, Deepak and Manda, Srinivas and Reddy, Pedavenkatagari Narayana},
title = {Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70249}
}
EUVIMED